Cover Image
市場調查報告書

年輕型骨髓單核細胞性白血病 (JMML) :全球臨床實驗檢討

Juvenile Myelomonocytic Leukemia (JMML) Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 298075
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
年輕型骨髓單核細胞性白血病 (JMML) :全球臨床實驗檢討 Juvenile Myelomonocytic Leukemia (JMML) Global Clinical Trials Review, H2, 2017
出版日期: 2017年10月31日 內容資訊: 英文 83 Pages
簡介

本報告提供全球年輕型骨髓單核細胞性白血病治療藥臨床實驗的相關調查,各地區,Phase別,各狀態臨床實驗趨勢,及主要企業和研究機關,醫院等臨床實驗簡介彙整,為您概述為以下內容。

目錄

簡介

  • 年輕型骨髓單核細胞性白血病
  • 報告指南

臨床試驗:各地區

  • 臨床試驗:各國
    • 對臨床實驗有所貢獻的前五國 - 亞太地區
    • 對臨床實驗有所貢獻的前五國 - 歐洲
    • 對臨床實驗有所貢獻的前幾名國家 - 北美
    • 對臨床實驗有所貢獻的前幾名國家 - 中南美

臨床試驗 G7各國

臨床試驗 G7各國,Phase別

臨床試驗 G7各國,各臨床實驗狀態

臨床試驗 Phase別

  • 進行中的臨床實驗:Phase別

臨床試驗:各臨床實驗狀態

未完成的臨床實驗

一定期間的被實驗人數

有力的贊助商

潛力治療藥物

臨床試驗簡介

  • 臨床試驗概要:前幾名企業
    • Merck & Co., Inc
  • 臨床試驗概要:最高級大學 / 研究機關 / 醫院
    • Fred Hutchinson Cancer Research Center
    • National Cancer Institute
    • Children's Oncology Group
    • Roswell Park Cancer Institute
    • Thomas Jefferson University
    • University of California, San Francisco
    • Columbia University
    • Wake Forest University
    • Masonic Cancer Center

5件主要臨床簡介

附錄

  • 簡稱
  • 定義
  • 調查方法
  • 二次調查
  • 關於GlobalData
  • 諮詢方式
  • 免責聲明
  • 資訊來源

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4683CTIDB

GlobalData's clinical trial report, "Juvenile Myelomonocytic Leukemia (JMML) Global Clinical Trials Review, H2, 2017" provides an overview of Juvenile Myelomonocytic Leukemia (JMML) clinical trials scenario. This report provides top line data relating to the clinical trials on Juvenile Myelomonocytic Leukemia (JMML). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
  • Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy:

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
    • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Juvenile Myelomonocytic Leukemia (JMML) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Juvenile Myelomonocytic Leukemia (JMML) to Oncology Clinical Trials
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source

List of Tables

  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials by Region, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, North America, Top Countries, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017*
  • Proportion of Juvenile Myelomonocytic Leukemia (JMML) to Oncology Clinical Trials, G7 Countries (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Juvenile Myelomonocytic Leukemia (JMML) to Oncology Clinical Trials, E7 Countries (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials by Phase, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures

  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials by Region (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017*
  • Proportion of Juvenile Myelomonocytic Leukemia (JMML) to Oncology Clinical Trials, G7 Countries (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Juvenile Myelomonocytic Leukemia (JMML) to Oncology Clinical Trials, E7 Countries (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials by Phase (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Juvenile Myelomonocytic Leukemia (JMML) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • GlobalData Methodology
Back to Top